Syndax Pharmaceuticals, Inc. SNDX
18.20
0.23
1.28%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow SNDX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(129.32%) | (161.82%) | (189.53%) | (255.93%) | |
| (63.74%) | (45.50%) | (43.70%) | (33.97%) | ||
ROIC |
(3,712.99%) | 0.00% | (573.79%) | (247.93%) | |
Return on Tangible Assets |
(74.94%) | (69.93%) | (63.15%) | (38.36%) | |
Average Days of Receivables |
134.61 | 144.31 | 98.98 | 101.57 | |
Free Cash Flow per Share |
(5.49) | (3.73) | (3.15) | (2.48) | |
Free Cash Flow |
(475.42) | (322.94) | (278.16) | (220.87) | |
Capital Expenditures |
(164.54) | 0.04 | — | (0.23) | |
Piotroski F-Score |
3.00 | 3.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(34.03%) | (39.28%) | (37.25%) | (19.06%) | |
Accounts Receivable Turnover |
5.00 | 4.34 | 5.55 | 4.78 | |
Accounts Payable Turnover |
0.46 | 0.49 | 0.83 | 0.96 | |
Inventory Turnover |
0.00 | 0.42 | 0.44 | 0.42 | |
Average Days of Payables |
1,182.68 | 868.25 | 453.97 | 167.09 | |
Days of Inventory on Hand |
2,138.50 | 1,715.24 | 1,463.18 | 1,136.93 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
220.23% | 150.15% | 117.87% | 103.89% | |
Selling, General and Administrative Expense of Revenue |
150.10% | 104.25% | 81.15% | 69.04% | |
Share Based Compensation of Revenue |
43.52% | 27.56% | 22.64% | 19.60% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 1.13 | 1.14 | 1.00 | |
Depreciation/Fixed assets |
(92.98) | (58.12) | (44.77) | (23.94) | |
Capex/Depreciation |
13.83 | 0.00 | 0.00 | 0.04 | |
Revenue per Share |
1.29 | 1.99 | 2.46 | 2.83 | |
Operating CF per Share |
(3.59) | (3.73) | (3.15) | (2.48) | |
Capex per Share |
(1.90) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.48 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(279.31%) | (165.60%) | (112.01%) | (87.60%) |
Columns are period end dates